Inogen Inc (NASDAQ:INGN) Receives $108.25 Average Price Target from Analysts

Inogen Inc (NASDAQ:INGN) has received an average recommendation of “Hold” from the eight ratings firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $108.25.

Several analysts have recently commented on the stock. Stifel Nicolaus upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and raised their price objective for the company from $11.00 to $17.00 in a research report on Wednesday, May 8th. JPMorgan Chase & Co. raised their price objective on shares of from GBX 385 ($5.03) to GBX 480 ($6.27) and gave the company an “overweight” rating in a research report on Wednesday, July 3rd. BidaskClub downgraded shares of Amyris from a “hold” rating to a “sell” rating in a research report on Thursday, June 27th. Finally, Needham & Company LLC upgraded shares of Smart Global from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a report on Friday, June 28th.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Lido Advisors LLC increased its holdings in Inogen by 4.3% in the 4th quarter. Lido Advisors LLC now owns 1,907 shares of the medical technology company’s stock valued at $236,000 after acquiring an additional 79 shares during the last quarter. Oregon Public Employees Retirement Fund increased its holdings in Inogen by 1.9% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 7,029 shares of the medical technology company’s stock valued at $670,000 after acquiring an additional 132 shares during the last quarter. Arizona State Retirement System increased its holdings in Inogen by 1.4% in the 1st quarter. Arizona State Retirement System now owns 12,845 shares of the medical technology company’s stock valued at $1,225,000 after acquiring an additional 178 shares during the last quarter. Stifel Financial Corp increased its holdings in Inogen by 8.5% in the 4th quarter. Stifel Financial Corp now owns 2,867 shares of the medical technology company’s stock valued at $355,000 after acquiring an additional 224 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in Inogen by 30.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,113 shares of the medical technology company’s stock valued at $138,000 after acquiring an additional 258 shares during the last quarter. Institutional investors own 98.61% of the company’s stock.

Shares of INGN stock traded up $0.51 on Friday, hitting $62.68. 244,170 shares of the stock traded hands, compared to its average volume of 420,756. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of 27.25, a price-to-earnings-growth ratio of 2.46 and a beta of 1.45. Inogen has a 52 week low of $61.35 and a 52 week high of $287.79. The business has a 50 day moving average price of $66.30. The company has a current ratio of 7.35, a quick ratio of 6.70 and a debt-to-equity ratio of 0.02.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, May 7th. The medical technology company reported $0.24 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.05). The firm had revenue of $90.20 million for the quarter, compared to the consensus estimate of $89.69 million. Inogen had a net margin of 12.56% and a return on equity of 15.59%. The firm’s revenue for the quarter was up 14.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.48 earnings per share. Analysts forecast that Inogen will post 1.63 earnings per share for the current fiscal year.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Story: LIBOR

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.